

# Brent A Orr

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7658716/publications.pdf>

Version: 2024-02-01

89  
papers

4,865  
citations

117625

34  
h-index

106344

65  
g-index

94  
all docs

94  
docs citations

94  
times ranked

7349  
citing authors

#	ARTICLE	IF	CITATIONS
1	New Brain Tumor Entities Emerge from Molecular Classification of CNS-PNETs. <i>Cell</i> , 2016, 164, 1060-1072.	28.9	702
2	Vismodegib Exerts Targeted Efficacy Against Recurrent Sonic Hedgehog-Subgroup Medulloblastoma: Results From Phase II Pediatric Brain Tumor Consortium Studies PBTC-025B and PBTC-032. <i>Journal of Clinical Oncology</i> , 2015, 33, 2646-2654.	1.6	368
3	cIMPACT-NOW update 6: new entity and diagnostic principle recommendations of the cIMPACT-Utrecht meeting on future CNS tumor classification and grading. <i>Brain Pathology</i> , 2020, 30, 844-856.	4.1	363
4	Active medulloblastoma enhancers reveal subgroup-specific cellular origins. <i>Nature</i> , 2016, 530, 57-62.	27.8	318
5	Resolving medulloblastoma cellular architecture by single-cell genomics. <i>Nature</i> , 2019, 572, 74-79.	27.8	273
6	Long Interspersed Element-1 Protein Expression Is a Hallmark of Many Human Cancers. <i>American Journal of Pathology</i> , 2014, 184, 1280-1286.	3.8	250
7	Risk-adapted therapy for young children with medulloblastoma (SJYC07): therapeutic and molecular outcomes from a multicentre, phase 2 trial. <i>Lancet Oncology</i> , The, 2018, 19, 768-784.	10.7	151
8	St. Jude Cloud: A Pediatric Cancer Genomic Data-Sharing Ecosystem. <i>Cancer Discovery</i> , 2021, 11, 1082-1099.	9.4	109
9	Outcomes by Clinical and Molecular Features in Children With Medulloblastoma Treated With Risk-Adapted Therapy: Results of an International Phase III Trial (SJMB03). <i>Journal of Clinical Oncology</i> , 2021, 39, 822-835.	1.6	106
10	Irreversible growth plate fusions in children with medulloblastoma treated with a targeted hedgehog pathway inhibitor. <i>Oncotarget</i> , 2017, 8, 69295-69302.	1.8	99
11	The molecular landscape of ETMR at diagnosis and relapse. <i>Nature</i> , 2019, 576, 274-280.	27.8	94
12	Germline Elongator mutations in Sonic Hedgehog medulloblastoma. <i>Nature</i> , 2020, 580, 396-401.	27.8	94
13	Genomes for Kids: The Scope of Pathogenic Mutations in Pediatric Cancer Revealed by Comprehensive DNA and RNA Sequencing. <i>Cancer Discovery</i> , 2021, 11, 3008-3027.	9.4	88
14	Pathology, diagnostics, and classification of medulloblastoma. <i>Brain Pathology</i> , 2020, 30, 664-678.	4.1	68
15	Disrupting LIN28 in atypical teratoid rhabdoid tumors reveals the importance of the mitogen activated protein kinase pathway as a therapeutic target. <i>Oncotarget</i> , 2015, 6, 3165-3177.	1.8	66
16	Alisertib is active as single agent in recurrent atypical teratoid rhabdoid tumors in 4 children. <i>Neuro-Oncology</i> , 2015, 17, 882-888.	1.2	64
17	Advances in the classification of pediatric brain tumors through DNA methylation profiling: From research tool to frontline diagnostic. <i>Cancer</i> , 2018, 124, 4168-4180.	4.1	64
18	Serial assessment of measurable residual disease in medulloblastoma liquid biopsies. <i>Cancer Cell</i> , 2021, 39, 1519-1530.e4.	16.8	64

#	ARTICLE	IF	CITATIONS
19	Molecular grouping and outcomes of young children with newly diagnosed ependymoma treated on the multi-institutional SJYC07 trial. <i>Neuro-Oncology</i> , 2019, 21, 1319-1330.	1.2	63
20	Inactivation of Ezh2 Upregulates Gfi1 and Drives Aggressive Myc-Driven Group 3 Medulloblastoma. <i>Cell Reports</i> , 2017, 18, 2907-2917.	6.4	61
21	Genomic analysis demonstrates that histologically-defined astroblastomas are molecularly heterogeneous and that tumors with MN1 rearrangement exhibit the most favorable prognosis. <i>Acta Neuropathologica Communications</i> , 2019, 7, 42.	5.2	57
22	Alternative lengthening of telomeres, ATRX loss and H3K27M mutations in histologically defined pilocytic astrocytoma with anaplasia. <i>Brain Pathology</i> , 2019, 29, 126-140.	4.1	54
23	A clinicopathologic study of diencephalic pediatric low-grade gliomas with BRAF V600 mutation. <i>Acta Neuropathologica</i> , 2015, 130, 575-585.	7.7	50
24	Molecular subgrouping of primary pineal parenchymal tumors reveals distinct subtypes correlated with clinical parameters and genetic alterations. <i>Acta Neuropathologica</i> , 2020, 139, 243-257.	7.7	50
25	Pediatric bithalamic gliomas have a distinct epigenetic signature and frequent EGFR exon 20 insertions resulting in potential sensitivity to targeted kinase inhibition. <i>Acta Neuropathologica</i> , 2020, 139, 1071-1088.	7.7	50
26	Oncogenic KRAS promotes malignant brain tumors in zebrafish. <i>Molecular Cancer</i> , 2015, 14, 18.	19.2	48
27	mTORC1-Mediated Inhibition of 4EBP1 Is Essential for Hedgehog Signaling-Driven Translation and Medulloblastoma. <i>Developmental Cell</i> , 2017, 43, 673-688.e5.	7.0	48
28	Retinoblastoma from human stem cell-derived retinal organoids. <i>Nature Communications</i> , 2021, 12, 4535.	12.8	48
29	Patient-derived orthotopic xenografts of pediatric brain tumors: a St. Jude resource. <i>Acta Neuropathologica</i> , 2020, 140, 209-225.	7.7	45
30	Subsequent neoplasms in survivors of childhood central nervous system tumors: risk after modern multimodal therapy. <i>Neuro-Oncology</i> , 2015, 17, 448-456.	1.2	44
31	An update on the central nervous system manifestations of Li-Fraumeni syndrome. <i>Acta Neuropathologica</i> , 2020, 139, 669-687.	7.7	44
32	Clinical and molecular heterogeneity of pineal parenchymal tumors: a consensus study. <i>Acta Neuropathologica</i> , 2021, 141, 771-785.	7.7	44
33	Pineoblastoma—The Experience at St. Jude Children's Research Hospital. <i>Neurosurgery</i> , 2017, 81, 120-128.	1.1	43
34	Clinical Outcomes and Patient-Matched Molecular Composition of Relapsed Medulloblastoma. <i>Journal of Clinical Oncology</i> , 2021, 39, 807-821.	1.6	40
35	Gliomatosis cerebri in children shares molecular characteristics with other pediatric gliomas. <i>Acta Neuropathologica</i> , 2016, 131, 299-307.	7.7	38
36	Risk-adapted therapy and biological heterogeneity in pineoblastoma: integrated clinico-pathological analysis from the prospective, multi-center SJMB03 and SJYC07 trials. <i>Acta Neuropathologica</i> , 2020, 139, 259-271.	7.7	36

#	ARTICLE	IF	CITATIONS
37	Relevance of Molecular Groups in Children with Newly Diagnosed Atypical Teratoid Rhabdoid Tumor: Results from Prospective St. Jude Multi-institutional Trials. <i>Clinical Cancer Research</i> , 2021, 27, 2879-2889.	7.0	35
38	Low-grade spinal glioneuronal tumors with BRAF gene fusion and 1p deletion but without leptomeningeal dissemination. <i>Acta Neuropathologica</i> , 2017, 134, 159-162.	7.7	33
39	Biology and grading of pleomorphic xanthoastrocytoma—what have we learned about it?. <i>Brain Pathology</i> , 2021, 31, 20-32.	4.1	32
40	Comprehensive molecular characterization of pediatric radiation-induced high-grade glioma. <i>Nature Communications</i> , 2021, 12, 5531.	12.8	31
41	Cervicomedullary tumors in children. <i>Journal of Neurosurgery: Pediatrics</i> , 2015, 16, 357-366.	1.3	29
42	Patient-derived models recapitulate heterogeneity of molecular signatures and drug response in pediatric high-grade glioma. <i>Nature Communications</i> , 2021, 12, 4089.	12.8	27
43	Lorlatinib in a Child with <i>ALK</i> -Fusion-Positive High-Grade Glioma. <i>New England Journal of Medicine</i> , 2021, 385, 761-763.	27.0	27
44	Malignant rhabdoid tumors originating within and outside the central nervous system are clinically and molecularly heterogeneous. <i>Acta Neuropathologica</i> , 2018, 136, 315-326.	7.7	26
45	Bithalamic gliomas may be molecularly distinct from their unilateral high-grade counterparts. <i>Brain Pathology</i> , 2018, 28, 112-120.	4.1	26
46	Phase I study of 5-fluorouracil in children and young adults with recurrent ependymoma. <i>Neuro-Oncology</i> , 2015, 17, 1620-1627.	1.2	24
47	The myogenesis program drives clonal selection and drug resistance in rhabdomyosarcoma. <i>Developmental Cell</i> , 2022, 57, 1226-1240.e8.	7.0	24
48	Unbiased Metabolic Profiling Predicts Sensitivity of High MYC-Expressing Atypical Teratoid/Rhabdoid Tumors to Glutamine Inhibition with 6-Diazo-5-Oxo-L-Norleucine. <i>Clinical Cancer Research</i> , 2019, 25, 5925-5936.	7.0	22
49	Malignant brainstem tumors in children, excluding diffuse intrinsic pontine gliomas. <i>Journal of Neurosurgery: Pediatrics</i> , 2016, 17, 57-65.	1.3	20
50	Central Nervous System-type Neuroepithelial Tumors and Tumor-like Proliferations Developing in the Gynecologic Tract and Pelvis. <i>American Journal of Surgical Pathology</i> , 2018, 42, 1429-1444.	3.7	18
51	The TORC1/2 inhibitor TAK228 sensitizes atypical teratoid rhabdoid tumors to cisplatin-induced cytotoxicity. <i>Neuro-Oncology</i> , 2017, 19, 1361-1371.	1.2	17
52	Mouse medulloblastoma driven by CRISPR activation of cellular Myc. <i>Scientific Reports</i> , 2018, 8, 8733.	3.3	17
53	Surgical and molecular considerations in the treatment of pediatric thalamopeduncular tumors. <i>Journal of Neurosurgery: Pediatrics</i> , 2017, 20, 247-255.	1.3	16
54	Functional loss of a noncanonical BCOR—PRC1.1 complex accelerates SHH-driven medulloblastoma formation. <i>Genes and Development</i> , 2020, 34, 1161-1176.	5.9	16

#	ARTICLE	IF	CITATIONS
55	Enophthalmos and Choroidal Atrophy after Intraophthalmic Artery Chemotherapy for Retinoblastoma. <i>Ophthalmology</i> , 2015, 122, 435-437.	5.2	14
56	YAP1-FAM118B Fusion Defines a Rare Subset of Childhood and Young Adulthood Meningiomas. <i>American Journal of Surgical Pathology</i> , 2021, 45, 329-340.	3.7	14
57	Primary cilia control translation and the cell cycle in medulloblastoma. <i>Genes and Development</i> , 2022, 36, 737-751.	5.9	14
58	Atypical teratoid/rhabdoid tumor (ATRT) arising from the 3rd cranial nerve in infants: a clinical-radiological entity?. <i>Journal of Neuro-Oncology</i> , 2015, 124, 175-183.	2.9	12
59	Marked functional recovery and imaging response of refractory optic pathway glioma to BRAFV600E inhibitor therapy: a report of two cases. <i>Child's Nervous System</i> , 2018, 34, 605-610.	1.1	12
60	Rapid and fulminant leptomeningeal spread following radiotherapy in diffuse intrinsic pontine glioma. <i>Pediatric Blood and Cancer</i> , 2017, 64, e26416.	1.5	11
61	Multiplatform Molecular Profiling Reveals Epigenomic Intratumor Heterogeneity in Ependymoma. <i>Cell Reports</i> , 2020, 30, 1300-1309.e5.	6.4	11
62	Molecular Pathways: Not a Simple Tube—The Many Functions of Blood Vessels. <i>Clinical Cancer Research</i> , 2015, 21, 18-23.	7.0	10
63	Preclinical Modeling of Image-Guided Craniospinal Irradiation for Very-High-Risk Medulloblastoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 103, 728-737.	0.8	10
64	An ABC Transporter Drives Medulloblastoma Pathogenesis by Regulating Sonic Hedgehog Signaling. <i>Cancer Research</i> , 2020, 80, 1524-1537.	0.9	10
65	NHERF1/EBP50 and NF2 as diagnostic markers for choroid plexus tumors. <i>Acta Neuropathologica Communications</i> , 2016, 4, 55.	5.2	9
66	<i>De novo</i> primary central nervous system pure erythroid leukemia/sarcoma with t(1;16)(p31;q24) NFIA/CBFA2T3 translocation. <i>Haematologica</i> , 2020, 105, e194-e197.	3.5	9
67	Prognostic Relevance of Treatment Failure Patterns in Pediatric High-Grade Glioma: Is There a Role for a Revised Failure Classification System?. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 99, 450-458.	0.8	8
68	Methylation profiling reveals novel molecular classes of rhabdomyosarcoma. <i>Scientific Reports</i> , 2021, 11, 22213.	3.3	8
69	WNT-activated embryonal tumors of the pineal region: ectopic medulloblastomas or a novel pineoblastoma subgroup?. <i>Acta Neuropathologica</i> , 2020, 140, 595-597.	7.7	7
70	Phase II study of alisertib as a single agent for treating recurrent or progressive atypical teratoid/rhabdoid tumor. <i>Neuro-Oncology</i> , 0, , .	1.2	7
71	H3 K27M Mutations in Thalamic Pilocytic Astrocytomas with Anaplasia. <i>World Neurosurgery</i> , 2019, 124, 87-92.	1.3	6
72	DNA Methylation Profiling Reveals Prognostically Significant Groups in Pediatric Adrenocortical Tumors: A Report From the International Pediatric Adrenocortical Tumor Registry. <i>JCO Precision Oncology</i> , 2019, 3, 1-21.	3.0	6

#	ARTICLE	IF	CITATIONS
73	Outcome and molecular analysis of young children with choroid plexus carcinoma treated with non-myeloablative therapy: results from the SJYC07 trial. <i>Neuro-Oncology Advances</i> , 2021, 3, vdaa168.	0.7	6
74	Oncogenic GOPC-ROS1 Fusion Identified in a Congenital Glioblastoma Case. <i>Journal of Pediatric Hematology/Oncology</i> , 2020, 42, e813-e818.	0.6	6
75	Treatment of pediatric high-grade central nervous system tumors with high-dose methotrexate in combination with multiagent chemotherapy: A single-institution experience. <i>Pediatric Blood and Cancer</i> , 2020, 67, e28119.	1.5	5
76	Molecular classification of a complex structural rearrangement of the RB1 locus in an infant with sporadic, isolated, intracranial, sellar region retinoblastoma. <i>Acta Neuropathologica Communications</i> , 2021, 9, 61.	5.2	5
77	Phase I study using crenolanib to target PDGFR kinase in children and young adults with newly diagnosed DIPG or recurrent high-grade glioma, including DIPG. <i>Neuro-Oncology Advances</i> , 2021, 3, vdab179.	0.7	5
78	Pre-operative embolization for staged treatment of infantile choroid plexus papilloma. <i>Child's Nervous System</i> , 2022, 38, 429-433.	1.1	4
79	Phase II study of alisertib as a single agent in recurrent or progressive atypical teratoid rhabdoid tumors.. <i>Journal of Clinical Oncology</i> , 2020, 38, 10542-10542.	1.6	4
80	Revised clinical and molecular risk strata define the incidence and pattern of failure in medulloblastoma following risk-adapted radiotherapy and dose-intensive chemotherapy: results from a phase III multi-institutional study. <i>Neuro-Oncology</i> , 2022, 24, 1166-1175.	1.2	2
81	MEDB-78. Unified rhombic lip origins of Group 3 and Group 4 medulloblastoma. <i>Neuro-Oncology</i> , 2022, 24, i124-i125.	1.2	1
82	ATRT-22. Outcomes for children with recurrent atypical teratoid rhabdoid tumor: A single institution study with updated molecular and germline analysis. <i>Neuro-Oncology</i> , 2022, 24, i8-i8.	1.2	1
83	PM-05 * TUMOR LOCATION REMODELS TRANSCRIPTOMIC PROFILES IN A PEDIATRIC MEDULLOBLASTOMA XENOGRAFT. <i>Neuro-Oncology</i> , 2015, 17, iii32-iii32.	1.2	0
84	Abstract 642: Genomes for Kids: Comprehensive DNA and RNA sequencing defining the scope of actionable mutations in pediatric cancer. , 2021, , .		0
85	OR02-1 DNA Methylation Profiling in Pediatric Adrenocortical Tumors Reveals Distinct Methylation Signatures with Prognostic Significance: A Report from the International Pediatric Adrenocortical Tumor Registry. <i>Journal of the Endocrine Society</i> , 2019, 3, .	0.2	0
86	ATP-dependent efflux transporter ABCC4 is a positive regulator of the Sonic Hedgehog signaling pathway. <i>FASEB Journal</i> , 2019, 33, 675.19.	0.5	0
87	BIOM-36. SERIAL ASSESSMENT OF MEASURABLE RESIDUAL DISEASE IN MEDULLOBLASTOMA LIQUID BIOPSIES. <i>Neuro-Oncology</i> , 2021, 23, vi18-vi19.	1.2	0
88	EPCO-26. INTEGRATIVE MULTI-OMICS IDENTIFIES CONVERGING DEVELOPMENTAL ORIGINS OF DISTINCT MEDULLOBLASTOMA SUBGROUPS. <i>Neuro-Oncology</i> , 2021, 23, vi7-vi7.	1.2	0
89	MEDB-42. Germline <i>Elp1</i> deficiency promotes genomic instability and survival of granule neuron progenitors primed for SHH medulloblastoma pathogenesis. <i>Neuro-Oncology</i> , 2022, 24, i115-i115.	1.2	0